Progyny

Progyny, Inc. is a fertility benefits management company. It provides fertility solutions to employers, managing IUI, in vitro fertilization (IVF), egg freezing, and other fertility treatments. It operates through one segment: fertility and pharmacy benefits solutions. It also delivers treatment services and access to the firm’s network of fertility specialist. The company was founded on April 3, 2008 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Progyny reports record growth in 2022, eyes sustained success

Progyny's exceptional performance in 2022, driven by record revenue growth and client additions, positions the company for continued success in 2023.
The company's strengths in provider network retention, strong gross margins, and strategic investments highlight its competitive advantage and growth potential.
Challenges such as tightening growth rates and margin sustainability require proactive strategies, while opportunities in market positioning and growth avenues offer promising prospects.
With a strong pipeline, focus on enhancing services, and commitment to growth, Progyny is poised to capitalize on market demand and drive further success.

Progyny reports record Q1 growth, raises 2023 guidance amid strong demand

Progyny's Q1 2023 performance reflects robust growth, operational efficiency, and a strategic focus on expanding market reach and service offerings. Despite potential challenges, the company remains optimistic about future prospects, raising guidance for 2023 and highlighting strong demand for fertility benefits.

Progyny reports record revenue and strong growth outlook for 2023

Progyny's Q2 2023 earnings call highlighted exceptional financial performance, strong operational metrics, and a positive outlook for future growth. The company's focus on quality care, cost containment, and market trends positions it well for continued success in the reproductive health industry.
With a robust PBM model, unique contracting approach, and commitment to data-driven outcomes, Progyny stands out as a leader in the sector. The expansion into menopause services and partnerships further strengthens its competitive edge and diversifies its service offerings.
While Progyny faces challenges in market penetration and operational scalability, the company's strategic strengths and growth opportunities present a promising outlook. By navigating industry challenges and leveraging emerging trends, Progyny is poised for sustained growth and innovation.

Progyny reports record Q3 earnings, eyes growth through diversification

Progyny's Q3 performance reflects robust growth, strong client relationships, and strategic expansion initiatives.
Despite challenges in Q4 and Progyny Rx contribution decline, the company is well-positioned for sustained growth.
Opportunities lie in diversifying services, addressing economic concerns, and leveraging partnerships for future expansion.
Overall, Progyny's proactive strategies and solid financial performance signal a promising outlook for continued success.

Progyny excels in 2023, eyes diversified growth in 2024

Progyny's exceptional 2023 performance and client-focused approach position it as a leader in fertility care.
While facing revenue challenges in Q1, Progyny's strategic initiatives and market opportunities offer avenues for growth.
The company's resilience in member activity and diversified revenue streams bode well for sustained success.
Progyny's expansion plans and competitive wins underscore its strong market position and growth potential.

Progyny reports strong Q1 performance, eyes growth opportunities ahead

Progyny's Q1 showed strength but faced challenges in utilization and revenue.
The company's business model demonstrated leverage and solid financial performance.
Opportunities lie in market trends, expanding services, and employer conversations.
Guidance for Q2 and full-year adjusted EBITDA indicates growth trajectory.
Progyny's focus on women's health and family building positions it for future success.

Progyny reports 9% revenue growth in Q2 2024 earnings call

Progyny delivered solid financial performance in Q2 2024, with revenue and gross profit showing healthy growth rates.
Despite challenges in forecasting and membership growth, the company's operational strengths and cash flow generation are notable.
Adjustments to revenue guidance reflect proactive management in response to market dynamics, while opportunities for growth and efficiency improvements are evident.
Overall, Progyny's Q2 performance highlights resilience and strategic focus amidst evolving market conditions.

Progyny reports mixed Q3 performance, focuses on client growth

Progyny faced challenges in member activity and gross margin in Q3 2024.
Despite this, positive selling season results and strong client commitments were noted.
Renewals and upsell activities remained robust, supporting revenue guidance.
The company's focus on care management services and cash flow stability is evident.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Progyny (PGNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Progyny (PGNY) Upgraded to Buy: Here's Why

Progyny is a leading benefit management company that specializes in fertility and family building. Their revenue has been growing at an amazing pace (80% per year, 5 year average).

Progyny: Solving Infertility Problem

SAN DIEGO--(BUSINESS WIRE)---- $PGNY #InvestorsRights--Robbins LLP Reminds Investors it is Investigating Progyny, Inc. (PGNY) on Behalf of Shareholders

PGNY STOCKHOLDER ALERT: Robbins LLP Reminds Investors it is Investigating Progyny, Inc. (PGNY) on Behalf of Shareholders

NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Jefferies 2022 Healthcare Conference on Wednesday, June 8, 2022 at 10:30 A.M. Eastern Time.

Progyny, Inc. to Present at the Jefferies 2022 Healthcare Conference

Progyny is a hidden gem tackling a prevalent and growing issue. With massive growth ahead and a solid competitive position, Progyny is a great addition to your portfolio.

Progyny Stock: A Hidden Gem Tackling Infertility

AMN Healthcare Services

AMN vs. PGNY: Which Stock Is the Better Value Option?

Arielle Bogorad joins Progyny as Senior Vice President of Employer Market Strategy Arielle Bogorad joins Progyny as Senior Vice President of Employer Market Strategy

Progyny Lands Employer Benefits Expert in Expansion of Leadership Team

SAN DIEGO--(BUSINESS WIRE)---- $PGNY #classactionlawyers--PGNY STOCK NEWS: Robbins LLP Investigates Progyny, Inc. (PGNY) on Behalf of Shareholders

PGNY STOCK NEWS: Robbins LLP Investigates Progyny, Inc. (PGNY) on Behalf of Shareholders

The inaugural grant will provide education, access to care, and financial assistance to either a couple or individual of color through their family building journey The inaugural grant will provide education, access to care, and financial assistance to either a couple or individual of color through their family building journey

The Broken Brown Egg and Progyny Launch the Awareness, Hope, and Activism Grant™ to Help BIPOC Individuals and Couples Expand their Families

Progyny, Inc. (NASDAQ:PGNY ) Q1 2022 Earnings Call Transcript May 5, 2022 5:00 PM ET Company Representatives Peter Anevski - Chief Executive Officer Michael Sturmer - President Mark Livingston - Chief Financial Officer James Hart - Vice President of Investor Relations Conference Call Participants Anne Samuel - JPMorgan Michael Cherny - Bank of America Sarah James - Barclays Glen Santangelo - Jefferies Stephanie Davis - SVB Securities Dev Weerasuriya - Berenberg Operator Good afternoon, ladies and gentlemen, and welcome to the Progyny Inc. First Quarter 2022 Earnings Conference Call. At this time, all participants have been on a listen-only mode and the floor will be opened for questions and comments after the presentation.

Progyny, Inc. (PGNY) CEO Peter Anevski on Q1 2022 Results - Earnings Call Transcript

Progyny (PGNY) delivered earnings and revenue surprises of 150% and 2.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Tops Q1 Earnings and Revenue Estimates

Incorporated in 2008, Progyny Inc. ( PGNY , Financial) is a leading benefits management company operating in the fertility space in the United States. The company operates as a third-party insurance company that manages fertility benefit plans, and the most famous product sold by the company is Smart Cycle.

Progyny: A Profitable High-Growth Company

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced executives from Progyny will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on Wednesday, May 11, 2022 at 11:40 A.M. Eastern Time, or 8:40 A.M. Pacific Time.

Progyny, Inc. to Present at the BofA Securities 2022 Healthcare Conference

Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Progyny (PGNY) to Report a Decline in Earnings: What to Look Out for

NEW YORK, April 21, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period ended March 31, 2022 after the close of the market on Thursday, May 5, 2022.

Progyny, Inc. Announces Details for Its First Quarter 2022 Results Report

The fertility benefits leader and national infertility nonprofit association take over the capital of the world to support the millions of people who need family building support The fertility benefits leader and national infertility nonprofit association take over the capital of the world to support the millions of people who need family building support

Progyny and RESOLVE to Launch National Infertility Awareness Week® by Ringing the Nasdaq Stock Market Opening Bell and Lighting the Empire State Building

Avantor Inc.

AVTR vs. PGNY: Which Stock Is the Better Value Option?

New York, New York--(Newsfile Corp. - March 24, 2022) - Moore Kuehn, PLLC, a securities law firm located on Wall Street, is investigating whether certain officers and directors of Progyny, Inc. (NASDAQ: PGNY) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms.If you own PGNY please contact Justin Kuehn, Esq. by email at jkuehn@moorekuehn.com or telephone at (212) 709-8245. The consultation...

Moore Kuehn, PLLC Encourages Investors of Progyny, Inc. to Contact Law Firm

Ortho Clinical Diagnostics Holdings

OCDX vs. PGNY: Which Stock Is the Better Value Option?

OCDX vs. PGNY: Which Stock Should Value Investors Buy Now?

NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, today announced that Pete Anevski, Progyny's Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a fireside chat at the Barclays Global Healthcare Conference on Tuesday, March 15, 2022 at 3:50 P.M. Eastern Time.

Progyny, Inc. to Present at the Barclays Global Healthcare Conference

Progyny, Inc. (PGNY) CEO Pete Anevski on Q4 2021 Results - Earnings Call Transcript

Progyny (PGNY) delivered earnings and revenue surprises of 275% and 6.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Progyny (PGNY) Surpasses Q4 Earnings Estimates

Issues Guidance for 2022, Reflecting 50% Revenue Growth at Midpoint of the RangeReports Full Year Revenue of $500.6 Million, Reflecting 45% GrowthReports Fourth Quarter Revenue of $127.6 Million, Reflecting 27% Growth

Progyny, Inc. Announces Fourth Quarter and Full Year 2021 Results

Earnings Preview: Progyny (PGNY) Q4 Earnings Expected to Decline

NEW YORK, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a leading benefits management company specializing in fertility and family building benefits solutions in the United States, will report its financial results for the quarterly period and full year ended December 31, 2021 after the close of the market on Monday, February 28, 2022.

News for Progyny Stock (PGNY)